BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1378 related articles for article (PubMed ID: 18502655)

  • 1. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
    J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
    Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
    J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.
    Fernandes HB; Baimbridge KG; Church J; Hayden MR; Raymond LA
    J Neurosci; 2007 Dec; 27(50):13614-23. PubMed ID: 18077673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
    Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
    Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
    Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
    J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
    Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
    J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
    Tang TS; Slow E; Lupu V; Stavrovskaya IG; Sugimori M; LlinĂ¡s R; Kristal BS; Hayden MR; Bezprozvanny I
    Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2602-7. PubMed ID: 15695335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
    Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
    Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
    Tang TS; Chen X; Liu J; Bezprozvanny I
    J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
    Li L; Murphy TH; Hayden MR; Raymond LA
    J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
    Bezprozvanny I
    Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
    Zeron MM; Hansson O; Chen N; Wellington CL; Leavitt BR; Brundin P; Hayden MR; Raymond LA
    Neuron; 2002 Mar; 33(6):849-60. PubMed ID: 11906693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
    Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
    J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.
    Li L; Fan M; Icton CD; Chen N; Leavitt BR; Hayden MR; Murphy TH; Raymond LA
    Neurobiol Aging; 2003 Dec; 24(8):1113-21. PubMed ID: 14643383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.